Price
CHART BY
Frequently asked questions
What is BTI's market capitalization?
The market capitalization of BTI is $16.92M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for BTI?
BTI's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.152. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for BTI's stock?
Currently, 4 analysts cover BTI's stock, with a consensus target price of $5.00. Analyst ratings provide insights into the stock's expected performance.
What is BTI's revenue over the trailing twelve months?
Over the trailing twelve months, BTI reported a revenue of $2.28M.
What is the EBITDA for BTI?
BTI's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$72.80M. EBITDA measures the company's overall financial performance.
What is the free cash flow of BTI?
BTI has a free cash flow of -$84.08M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does BTI have, and what sector and industry does it belong to?
BTI employs approximately 74 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of BTI's shares?
The free float of BTI is 41.10M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $16.92M
- EPS (TTM)
- -$2.152
- Free Float
- 41.10M
- Revenue (TTM)
- $2.28M
- EBITDA (TTM)
- -$72.80M
- Free Cashflow (TTM)
- -$84.08M
Pricing
- 1D span
- $0.289$0.345
- 52W span
- $0.302$4.17
Analyst Ratings
The price target is $5.00 and the stock is covered by 4 analysts.
Buy
3
Hold
1
Sell
0
Information
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
- Employees
- 74
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US09075P1057
- Primary Ticker
- BTAI